Evogene (NASDAQ:EVGN) Issues Earnings Results, Misses Estimates By $0.33 EPS

Evogene (NASDAQ:EVGN) issued its earnings results on Wednesday. The biotechnology company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33), FiscalAI reports. The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

Here are the key takeaways from Evogene’s conference call:

• Evogene said it is sharpening its strategy around ChemPass AI and two core markets: small-molecule pharma and next-generation ag chemicals, with a business model built on partnerships and internally funded pipeline development.
• The company highlighted continued momentum in AI platform development, including a second collaboration with Google to build AI agents that could extract scientific insights and generate proprietary datasets for better molecule design.
• Evogene’s Pharma Division added three new collaborations in Q1, targeting inflammatory disease, demyelinating disorders, and chemotherapy resistance, which management said expands a growing small-molecule pipeline.
• In ag chemicals, AgPlenus and Bayer terminated their herbicide research collaboration after target biology issues limited further development, though management said the relationship remains constructive and future collaboration is possible.
• The internal Septoria fungicide program showed strong progress: iterative AI-guided screening materially improved hit rates, and the company now has high expectations for advancing the lead set.
• Evogene ended Q1 with about $13.1 million in cash and a $5.9 million net loss, while revenues fell sharply year over year to about $0.3 million due mainly to lower Casterra seed sales.

Evogene Trading Down 3.2%

Shares of EVGN opened at $0.72 on Thursday. The company has a market cap of $6.28 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. Evogene has a 1-year low of $0.68 and a 1-year high of $2.42. The company’s fifty day simple moving average is $0.80 and its 200 day simple moving average is $0.96.

Hedge Funds Weigh In On Evogene

A number of institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC lifted its position in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 36,206 shares during the period. XTX Topco Ltd bought a new stake in Evogene during the fourth quarter worth about $25,000. Finally, Jane Street Group LLC lifted its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares during the period. 10.40% of the stock is currently owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.